J.B.CHEMICALS & PHARMACEUTICALS LTD.
P&L
Quarterly Consolidated
vs Q4 FY25
JB Pharma Reports 9% Revenue Growth to INR 1094 Crores in Q1 FY26
30 Jul 2025 · 30 Jul 2025, 06:15 pm
Summary
JB Chemicals & Pharmaceuticals Ltd, also known as JB Pharma, has announced its financial results for the quarter ended on 30th June 2025. The company reported a 9% increase in revenue, which stood at INR 1,094 crores. The operating EBITDA increased by 13% to INR 330 crores, and the net profit rose by 14% to INR 202 crores. The domestic business recorded approximately 14% value growth, driven by acute and chronic segments, including the ophthalmology portfolio. The CDMO business momentum is expected to sustain in the coming quarters. The company's Operating EBITDA margins crossed 30% for the first time.
Key Highlights
- 1
Revenue growth of 9% to INR 1094 crores
- 2
Operating EBITDA increased by 13% to INR 330 crores
- 3
Net Profit increased by 14% to INR 202 crores
- 4
Domestic business recorded approx. 14% value growth
- 5
CDMO business momentum expected to sustain
- 6
Operating EBITDA margins crossed 30% for the first time
Management Comments
Mr. Nikhil Chopra
JB continues to be the fastest growing domestic pharma company amongst top 25 organizations as per IQVIA MAT Jun’25 data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to sustain in coming quarters. Our Operating EBITDA* margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth.
Informational and educational content only. Not investment advice.